Introduction
National chronic obstructive pulmonary disease (COPD) recommendations are a vital tool to assist health professionals in keeping abreast of the latest medicines and treatment options for patients with the condition. With the advent of many new therapies in the last few years, an update of the 2013 Swiss guidelines is warranted to ensure effective management of patients. The update includes stable COPD and acute exacerbation management recommendations based on the international GOLD Global Strategy for the Diagnosis, Management and Prevention of COPD 2018 report, published online on the GOLD website, as well as best evidence from the literature and other published national guidelines in Europe ( Table 1 ). The updated GOLD 2018 report published broader inclusion criteria, which means there may be more patients affected by COPD than previously diagnosed.
Based on the GOLD 2018 report, this update incorporates a new definition of COPD, as well as an updated ABCD assessment tool that enables inclusion of a broader patient population. A personalized approach is advocated. As before, this update recommends evaluation for COPD in individuals with a history of risk factors or with dyspnea, chronic cough, or sputum production, using a post-bronchodilator forced expiratory volume in one second/forced vital capacity (FEV 1 /FVC) cut off ratio less than 70% for diagnosis. However, the role of spirometry in the overall management of COPD is amended to include a combined assessment that separates symptoms, exacerbation history and the patient's overall health. Pharmacotherapy changes for stable COPD have been updated to reflect the latest randomized controlled trial data, which confirms the benefits of fixed dose triple bronchodilator therapy in stable COPD patients. Another addition to these recommendations is a slight change in the definition of an exacerbation, which is simplified and more practical for the clinical setting. Non-drug interventions and lifestyle measures such as smoking cessation programs, vaccinations and pulmonary rehabilitation is recommended, and usage of these resources should be maximized in all COPD patients.
Definition
COPD is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases [12] . The revised GOLD definition of COPD, endorsed by both the American Thoracic Society and the European Respiratory Society (ERS), takes into consideration the impact of respiratory symptoms and the role of lung tissue and airway abnormalities in the development of COPD [12] .
Burden of Disease
Although COPD is largely a preventable and treatable disease, analysis of the incidence of respiratory symptoms shows that COPD is a major disease burden in Europe [13] . It is often underdiagnosed or misdiagnosed in Swiss primary care and hence prevalence and mortality figures are significantly underestimated [14, 15] . Measured airflow obstruction prevalence of up to 10% for adult patients (GOLD stage ≥2) is estimated in the Swiss Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) cohort [16] . This study also shows that the prevalence of COPD is largely age dependent.
Mortality from COPD accounts for almost 50% of all respiratory disease deaths in Switzerland [17] . Approximately 2.6% of all hospitalizations are related to COPD in Swiss patients [14] . Cigarette smoking is the most common risk factor for COPD, but other environmental exposures and host factors may contribute (e.g., occupational exposures, biomass fuels, α1-antitrypsin deficiency) [12] . Individual susceptibility to infections plays a role in exacerbations [12] .
COPD is a debilitating and chronic disease that carries a significant and substantial socioeconomic burden on individuals and society. Direct COPD-related costs increase with disease severity. In Sweden, direct costs from COPD are reported as EUR 7,320 for mild, EUR 8,280 for moderate, EUR 9,230 for severe and EUR 11,810 for very severe disease [18] . Indirect costs such as the inability to work may be affected in individuals with the disease [18] . In 2012, the average income of a Swedish COPD patient was less than half of what a non-COPD patient earns (EUR 11,500 vs. EUR 29,000 in 2012) [18] .
The diagnostic process for COPD should be multidimensional and include a detailed medical history, physical examination and measurement of airflow obstruction. Prompt and accurate diagnosis enables early intervention, therefore, according to the most recent GOLD strategy, a diagnosis of COPD should be considered in any patient with a history of exposure to risk factors (e.g., tobacco smoking) and/or with dyspnea (progressive, on exertion or persistent), chronic cough or sputum production [12] . Post-bronchodilator spirometry (FEV 1 /FVC ratio < 70%) is required for confirmation of a diagnosis [12] . Confirm with repeated spirometry measurements the absence or presence of airflow obstruction in patients with an FEV 1 /FVC ratio between 60 and 80%, as this ratio may change due to biological variability [12] .
Medical History
A focused history should be collected in patients with suspected COPD and should include (1) key symptoms such as dyspnea, chronic cough, and sputum production; (2) smoking habits (including quantification of cumulative smoking history, that is, how many packs per year); (3) exposure to other risk factors (i.e., occupational or environmental exposures); (4) past medical history, including asthma and respiratory infections in childhood; (5) family history of COPD or other chronic respiratory disease; (6) pattern of symptom development; (7) history of exacerbations or previous hospitalizations for respiratory disorders; (8) presence of comorbidities, (9) impact of disease on patient's life; (10) opportunities for reducing risk factors (e.g., smoking cessation); and (11) family and social support [12] .
Physical Examination
Diagnosis of COPD cannot be made on clinical signs alone, but these may be suggestive of COPD severity [12] . The sensitivity and specificity of a physical examination in detecting mild to moderate COPD are relatively poor due to the slow progressive nature of the disease; there may be no clinical signs or symptoms attributable to aging or smoking [12] . Consequently, COPD is most often diagnosed in the advanced stage when physical signs of airflow obstruction and pulmonary hyperinflation have developed [12] . Chest auscultation may or may not detect crackles or wheezing with a prolonged expiratory phase [12] . Evidence of fatigue, weight loss and anorexia may be noted in severe cases of COPD [12] . Notably, chronic respiratory symptoms may precede airflow limitation and may be associated with the development of acute respiratory events; symptoms may also exist in patients with normal spirometry.
Pulmonary Function Testing
Spirometry should be performed when COPD is suspected and remains the most sensitive and important test for making a diagnosis of COPD. The GOLD guidelines suggest that in patients with a FEV 1 /FVC ratio < 70%, the presence of a post-bronchodilator FEV 1 of ≥80%, 50% to < 80%, 30% to < 50% or < 30% of the predicted value, presents a mild, moderate, severe or very severe airflow limitation severity in COPD respectively [12] .
Combined Assessment
The updated GOLD guidelines recommend a combined assessment approach to group patients according to airflow, impact of the patient's symptoms on daily living, and patient's future risk of experiencing an exacerbation [12] . The "ABCD" assessment tool has been revised to reflect spirometry-confirmed diagnosis, in conjunction with symptoms and exacerbation history for prognosis and therapeutic considerations (Fig. 1) . The ABCD assessment tool allows individual assessment to determine the classification of disease severity and hence achieve better stratification of patients.
Assessment of Severity of Airflow Limitation
The presence of airflow limitation is indicated by a reduced post-bronchodilator FEV 1 /FVC ratio of < 70% and an FEV 1 of < 80%. The GOLD classification categorizes airflow limitation into stages based on post-bronchodilator FEV 1 predictions ( Table 2) .
Assessment of Symptoms
The impact of respiratory symptoms on a patient's life should be assessed by the modified Medical Research Council (mMRC) questionnaire and the COPD Assessment Test (CAT TM ) or the COPD Control questionnaire (CCQ ® ) [12] . Shortness of breath during exercise is one of the primary symptoms of COPD, and the mMRC dyspnea scale should be used to grade the breathlessness according to the level of exertion required to elicit it (Table 3 ) [12] . The CAT and CCQ are simple scoring methods that have a broader coverage of the impact of COPD on the patient's daily life and well-being and correlate closely with health status impairment measured using the more complex St. Georges Respiratory Questionnaire [12] . CAT is a standard and validated assessment tool containing 8 items for the evaluation of the impact of COPD on health status; each response is graded 0-5 with a higher score indicating worse health status (Table 4 ) [12] . It has also been translated into several languages and can easily be completed online at www. catestonline.org.
Assessment of Exacerbation Risk
An exacerbation is defined as an acute worsening of respiratory symptoms resulting in additional therapy. Frequent exacerbations have a high correlation with increased hospitalizations and an increased risk of mortality. Risk of exacerbation is divided into 4 groups (A, B, C, DOI: 10.1159/000490551 D; Fig. 1 ). Patients are deemed to have a high exacerbation risk (group C or D) if they have a history of 2 or more exacerbations or more than one exacerbation leading to hospitalization in the past year [12] .
Eosinophilia is a good predictor of viral exacerbations [19] . High eosinophil blood counts may predict increased exacerbation rates in patients treated with long-acting beta-agonist (LABA) bronchodilators without inhaled corticosteroids (ICS) [12] .
Assessment of Comorbidities
Patients with COPD are frequently affected by comorbidities, including cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis, depression, anxiety and lung cancer. Comorbidities potentiate the morbidity of COPD and influence mortality and hospitalizations independently. Routinely monitor and adequately treat comorbidities in all COPD patients. Treatment of comorbidities should not change COPD management [12] .
Alpha-1 Antitrypsin Deficiency
Screening for alpha-1 antitrypsin deficiency (AATD) is recommended for all patients with diagnosed COPD. A low concentration (< 20% normal) is highly suggestive of homozygous deficiency. Family members should be screened and together with the patient, referred to specialist centres for advice and management [12] . Almost 50% of the patients with AATD experience more frequent exacerbations than COPD patients without AATD [20] . In Switzerland, the mean number of individuals with AATD is estimated at 7,423 based on a population of 7.45 million [21] .
Complementary Investigations
Radiological Imaging COPD cannot be diagnosed based on a chest X-ray, but a chest X-ray may be valuable during the initial evaluation to exclude other diseases and to establish the presence of significant comorbidities such as concomitant respiratory, skeletal and cardiac disease [12] . Consider CT of the chest not only for the differential diagnosis, but also for detection of concomitant bronchiectasis, screening for lung cancer, assessment for lung-volume-reduction procedures and lung transplantation [12] .
Lung Volumes and Diffusing Capacity
Pathological changes occurring in COPD can lead to static hyperinflation of the lungs. Measurement of lung volumes by body plethysmography can help characterize COPD severity [12] . Moreover, the evaluation of the residual volume is essential to establish the indication for lung-volume reduction [11] . Measurement of the diffusing capacity of the lungs for carbon monoxide (DLCO) may be considered to provide an index of the severity of tissue destruction in emphysema [22] .
Pulse Oximetry
Pulse oximetry provides a method for rapid assessment of short-term respiratory compromise. It is recommended for all patients with clinical signs suggestive of right heart failure or respiratory failure. Pulse oximetry may be useful in identifying possible hypoxic patients who require supplementary oxygen therapy or in determining which patients require arterial blood gas measurements [12, 23] .
Exercise Testing
The objective assessment of exercise capacity in patients with limited exercise tolerance is a useful tool in COPD prognosis, in the assessment of health status, as well as, in the assessment of the effectiveness of pulmonary rehabilitation. The paced shuttle walk test and unpaced 6-min walk test are common test modalities [12] .
Composite Scores
The BODE index assigns scores to 4 variables (body mass index, obstruction, dyspnea and exercise) to give a composite score that better predicts mortality than each single variable [12] .
More recently, the B-AE-D index, namely, body mass index (B), frequency of severe acute exacerbations of COPD (AE) and mMRC dyspnea severity (D) has been identified as including the most suitable composite markers for simple and accurate risk assessment in COPD [24] . B-AE-D, plus copeptin, if available, is a COPD-specific prognostic [24] .
Differential Diagnosis
It can be challenging to differentiate between COPD and asthma with chronic airflow limitation in some patients (Table 5 ). In patients with common features of both asthma and COPD, a diagnosis of Asthma-COPD Overlap Syndrome or Asthma-COPD Overlap (ACO) may be given. As the role of biologics in the treatment of ACO is still being defined, ACO should be treated according to the dominant phenotype [25] . Additional potential differential diagnoses are easier to distinguish from COPD and include congestive heart failure, bronchiectasis, tuberculosis, obliterative bronchiolitis and diffuse panbronchiolitis [12] .
Methodology
Levels of evidence assigned to management recommendations are based largely on the GOLD report, which uses the evidence-ranking system of the US National Heart, Lung and Blood Institute, and was used in the previous Swiss guidelines (Table 6 ) [12] .
Preventive Therapy
Prevention and appropriate preventive therapy can alleviate the impact of COPD on public health [12] .
Smoking Cessation
Smoking cessation remains the most effective intervention that reduces lung function decline in COPD and therefore should be the top priority for all COPD patients (Evidence A) [12] . Studies show that smoking cessation slows the annual decrease of FEV 1 to a rate comparable to that of non-smokers [30] . In a Swedish study of COPD smokers, the long-term smoking cessation success rate (after 3 years) was 38% for subjects who took part in smoking cessation groups, compared to only 10% for subjects in the control group [31] . A systematic review shows that more intensive recruitment strategies that require increased patient contact, improve recruitment of patients into smoking cessation programmes (Evidence A) [32] . Smoking cessation rates also improve when smokers are provided with pharmacotherapy [33] .
Pharmacotherapy, including nicotine replacement therapy, is effective in supporting smoking cessation attempts and should be prescribed in the absence of contraindications [12] . A meta-analysis evaluating 7,332 patients with COPD reported that the combination of cognitive behavioural therapy (CBT) and nicotine replacement therapy was [34] . Electronic cigarette products are becoming increasingly popular [35] . However, their efficacy and safety are not well defined and thus their widespread use is not advocated [12] . Varenicline [36] , bupropion [37] and nortriptyline [38] are recommended in conjunction with supportive intervention programmes to increase longterm smoking cessation rates (Evidence A) [12, 38] . Furthermore, smoking reduces, at least partially, the impact of ICS on FEV 1 and peak expiratory flow [39] .
Vaccinations
Patients with COPD are particularly vulnerable to influenza, with evidence for increased incidence and severity of infection [40] . Influenza vaccines are recommended to reduce serious illness and mortality in COPD patients [12] . A Cochrane review reported that an inactivated influenza vaccine reduces the incidence of influenza-related respiratory infections (Evidence B) [41] . Patients with COPD who were administered an inactivated influenza vaccine experienced significantly fewer exacerbations per year than patients with COPD who were administered a placebo [40] .
A pneumococcal vaccination provides some protection against community-acquired pneumonia (CAP) and is recommended for all COPD patients ≥65 years of age [12] . For younger COPD patients, the vaccination is recommended if significant comorbidities, such as chronic heart or lung disease, are present [12] . The Federal Office of Public Health recommends a single dose of conjugated 13-valent vaccine (Prevenar-13), with no booster doses [41] . Pneumococcal polysaccharide vaccine (Pneumovax) is no longer recommended because of limited efficacy and because antibody levels may diminish with repeat doses ("immune exhaustion"). A recent systematic review showed that when COPD patients were given the pneumococcal vaccine, they had a lower likelihood of developing CAP compared to COPD patients receiving a control substance (OR 0.62, 95% CI 0.43-0.89; 6 studies, n = 1,372; Evidence B) [42] . Pneumococcal vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39-0.93; 4 studies, n = 446; Evidence B) [42] .
Pharmacological Management of Stable COPD
None of the existing medications for COPD has been conclusively shown to modify the long-term decline in lung function that is the hallmark of this disease [12] . Spe- cifically designed trials are required to confirm the post hoc evidence of such an effect with long-acting bronchodilators and/or ICS [12] . Until then, the main goals with current pharmacotherapy continue to reduce symptoms, reduce frequency and severity of exacerbations and improve exercise tolerance and health status [12] . Treatment should be individualized. Medication choice depends on availability, cost, the patient's preference and clinical response weighed against the side effects [12] . Existing guidelines advocate the use of long-acting bronchodilators as the frontline therapy for COPD, followed by dual combination long-acting bronchodilation if symptoms persistent and regular inhaled corticosteroid therapy is administered as an adjunct in patients experiencing frequent exacerbations. However, the latest longterm data reports that a single inhaler triple therapy with ICS/LABA/long-acting anti-muscarinic agent (LAMA) is superior to standard therapy with a dual combination ICS/LABA or LAMA therapy [43] or tiotropium alone in stable COPD patients [43, 44] . Moreover, escalation from an ICS/LABA or LAMA combination to triple therapy (ICS/LABA/LAMA) using a single inhaler could improve patient adherence to treatment [43, 44] . Addition of LAMA to ICS/LABA could improve lung function and patient-reported outcomes [12] .
Bronchodilators
Inhaled bronchodilators are commonly used in the management of airflow obstruction because they exert a direct relaxant effect on bronchial smooth muscle cells, thereby alleviating bronchial obstruction and airflow limitation, reducing hyperinflation and improving exhalation and exercise performance (Evidence A) [45] .
The inhalation method is preferred above oral bronchodilators because it maximizes the bronchodilator effect on the airways while minimizing side effects (Evidence A) [12] . There are 3 major classes of inhaled bronchodilators: (1) beta-2-adrenergic agonists (both short-and long-acting), (2) muscarinic receptor antagonists (both short-and long-acting) and (3) systemic phosphodiesterase inhibitors (methylxanthines). Relaxation of bronchial smooth muscle is caused by blocking acetylcholine activity at the receptor (muscarinic antagonists) or stimulating the G-proteincoupled receptor (beta-2-agonists) [46] . Recent guidelines published by the American College of Physicians (ACP), American College of Chest Physicians (ACCP), American Thoracic Society and ERS do not support bronchodilator treatment in asymptomatic COPD patients [47] .
Short acting beta-2-agonists (SABAs) and muscarinic antagonists (SAMAs) are equally effective and used for both acute and chronic management of COPD. Regular and as-needed use of SABAs and SAMAs improve FEV 1 and respiratory symptoms (Evidence A) [12] . SABAs have a short duration of action of 4-6 h [12] .
A fixed-dose combination of any LABA and LAMA should be considered above monotherapy (Evidence A) [12] . Regardless of the drugs used, LAMA/LABA fixeddose combinations are generally more effective than the respective monotherapies in terms of improvement in trough FEV 1 , transitional dyspnea index (TDI) and St. Georges Respiratory Questionnaire scores [48] . Compared to treatment with a LABA, LAMA monotherapy has a greater impact on reducing exacerbation rates (Evidence A) and hospitalizations (Evidence B) [12] .
A post hoc analysis of the TONADO ® studies showed that the once-daily combination of LAMA/LABA (tiotropium/olodaterol) significantly improved lung function in GOLD II, GOLD III and GOLD IV patients, compared to tiotropium alone, irrespective of whether patients had received prior LAMA or LABA maintenance treatment [49] . Further subgroup analyses suggested that this combination should be considered for maintenance therapy in patients with moderate to severe COPD [50] .
In general, LABAs and LAMAs are prescribed on a regular basis, as maintenance therapy, to improve lung function, dyspnea and health status and to reduce exacerbation rates (Evidence A) [12] . Twice-daily LABAs such as salmeterol and formoterol have an extended duration of action that is maintained for 12 h after single dose inhalation [51] . Both SABAs and LABAs are generally well tolerated but may cause resting sinus tachycardia and tremor [52] .
Head-to-head trials show that LAMAs are superior to SAMAs for maintenance therapy [53] . LAMA (tiotropium) treatment shows a greater effect on exacerbation rates in clinical trials compared to once-daily LABA (indacaterol) treatment [54] . Dry mouth is one of the most common side effects encountered with LAMAs, attributable to its anticholinergic action [55] . Adverse event rates are similar to placebo in clinical trials [52] .
Methylxanthines
Theophylline is a nonspecific phosphodiesterase inhibitor that can improve lung function, arterial blood gas tensions and walking distance compared to placebo [56] . It has a modest bronchodilator effect on FEV 1 and FVC in moderate to severe COPD [57] . Theophylline in combination with beta-2-agonists improves dyspnea more than theophylline monotherapy [58] . In a study by Thomas et al. [59] , theophylline plus salbutamol significantly improves FEV 1 by 31.3% compared to only 13.5 and 16.2% with the monotherapies respectively. However, theophylline combined with beta-2-agonists is non-superior to the use of beta-2-agonists alone [58] .
Inhaled Corticosteroids
Compared to placebo, ICS reduces post-bronchodilator FEV 1 and exacerbation rate but has no significant effect on mortality [60] . A systematic review, which included data from the large TORCH (TOwards a Revolution in COPD Health) study, shows a smaller improvement in lung function (prebronchodilator FEV 1 ) with ICS compared to LABA (MD -18.99 mL; 95% CI -37.46 to -0.52) and the risk of pneumonia is significantly greater with ICS than with LABA (OR 1.38; 95% CI 1.10-1.73) [61] . The combination LABA/ICS potentiates the positive effects of the ICS therapy, thus long-term monotherapy with ICS is not recommended for stable COPD (Evidence A) [12] . A meta-analysis of several studies evaluating the combination LABA/ICS shows a significant decrease in exacerbation rate and mortality compared to placebo [62] .
Data from the OPTIMO (Real-Life study On the aPpropriaTeness of treatment In MOderate COPD patients) [63] and WISDOM (Withdrawal of Inhaled Steroids during Optimized Bronchodilator Management) [64] trials shows that gradually withdrawing ICS therapy in selected patients with stable COPD at low risk of exacerbation does not increase the risk for exacerbations. Withdrawal of ICS therapy has been suggested in GOLD III COPD patients with normal blood eosinophil count (< 150 eosinophils/mm 3 ) and a limited history of exacerbations (< 2 exacerbations per year) [65, 66] .
In the FLAME trial, the first large, randomized, controlled head-to-head trial assessing combination LABA/ LAMA versus combination LABA/ICS in COPD patients with a history of exacerbations, indacaterol-glycopyrronium (LABA/LAMA) therapy was superior to salmeterol-fluticasone (LABA/ICS) therapy in preventing exacerbations, improving lung function and healthrelated quality of life in COPD patients [67] . However, the IMPACT study, which randomised over 10,000 patients with COPD to LAMA/LABA/ICS (umeclidinium, vilanterol, fluticasone furoate) LAMA/LABA (umeclidinium, vilanterol) and LABA/ICS (vilanterol, fluticasone furoate) for 52 weeks, showed superior outcomes for the combination LABA/ICS as compared to the dual bronchodilation with LABA/LAMA [70] . The fact that most patients were on ICS before inclusion and that "history of asthma" was not an exclusion criteria for the IMPACT study could partially explain the superiority of LABA/ICS versus LAMA/LABA in IMPACT as much as the exclusion of all patients deteriorating during the run-in phase (on LAMA only) of FLAME could explain the superiority of dual bronchodilation versus LABA/ ICS in that trial. In addition, it is also tempting to hypothesize that the differences in the particular bronchodilators used in FLAME (indacaterol vs. salmeterol) could additionally account for the differences between both regimens. There is consensus that not all patients with COPD will benefit from ICS. Those with more severe disease as assessed by airflow obstruction or respiratory symptoms, those with asthmatic features, as well as those with higher circulating eosinophils counts might profit the most from ICS [12] . Further randomized, prospective studies are needed to validate recommendations related to specific patient populations.
The recent PREVENT study, a recent randomized, placebo-controlled trial including GOLD II-IV patients explored whether increasing the dose of an already established combination treatment (LABA/ICS) at the onset of an upper respiratory tract infection (URTI) could reduce the incidence of subsequent COPD exacerbations for the following 21 days, compared to staying on the low-dose LABA/ICS [68] . Patients receiving low-dose formoterol (12 μg/day) and budesonide (400 μg/day) doubled the doses of LABA/ICS for 10 days following the onset of URTI symptoms. The risk for the development of a severe exacerbation (hospital admission) within 21 days of a URTI was significantly decreased by 72% compared to the placebo group. COPD patients with more severe disease (FEV 1 < 50%) or at higher risk (GOLD C and D) also showed a reduction in the risk of exacerbation. Thus, for the first time, a study has shown that hospital admissions can be prevented by targeting URTIs with increased short term LABA/ICS.
Triple Inhaled Therapy
A randomized study by Aaron et al. [69] showed that combined therapy with fluticasone-salmeterol plus tiotropium may have beneficial effects on quality of life, lung function and hospitalizations without an increase in serious adverse events. Long-term data from the TRILOGY (Single Inhaler Triple Therapy Versus Inhaled Corticosteroid Plus LABA Therapy for COPD) [43] and TRINITY [44] trials demonstrates that single-inhaler triple therapy (ICS/LAMA/LABA) has the propensity to simplify medication regimens, provide greater efficacy, reduce exacerbations and has a greater effect on health-related quality of life than standard treatment. The primary results of the DOI: 10.1159/000490551 TRILOGY study showed a statistically significant improvement in pre-dose FEV 1 in the triple therapy group of 0.081 L (p < 0.001) and 2-h post-dose FEV 1 of 0.117L (p < 0.001) [43] . Adverse events were similar between triple and dual study groups and were typically mild to moderate in severity [43] . TRINITY is a multicentre study evaluating triple therapy in adult patients with severe or very severe COPD [44] . Patients were randomized to 1 of 3 treatment regimens: LAMA alone (tiotropium), fixed triple therapy ICS/LABA/LAMA (beclomethasone/formoterol/glycopyrronium), or triple therapy with ICS/ LABA (beclomethasone/formoterol) plus LAMA (tiotropium) taken separately [44] . The fixed triple combination demonstrated a reduction in moderate and severe exacerbations compared to tiotropium (rate ratio 0.80 [95% CI 0.69-0.92]; p = 0.0025). Non-inferiority between the fixed dose triple therapy and dual combination plus tiotropium was demonstrated, with a mean difference in pre-dose FEV 1 of -0.003 L (95% CI -0.033 to 0.027) [44] . Recently, triple therapy with LAMA/LABA/ICS proved to be superior to dual bronchodilator therapy with LAMA/LABA, decreasing exacerbation rate by 15% and showing no association with an increased risk of pneumonia. The IMPACT study confirmed superior outcomes for the triple therapy, LAMA/LABA/ICS (umeclidinium, vilanterol, fluticasone furoate) as compared to LAMA/LABA (umeclidinium, vilanterol) and LABA/ICS (vilanterol, fluticasone furoate) including the rate of moderate or severe exacerbation (0.91 vs. 1.21 and 1.07 per year, respectively) [70] . Mortality was also significantly reduced in patients receiving the triple therapy [70] . The incidence of pneumonia was, however, significantly increased in patients receiving an ICS [70] . Therefore, triple therapy should be considered in selected, symptomatic patients with severe airflow obstruction and at least one exacerbation in the previous year [71] .
Oral Corticosteroids
Oral corticosteroids may improve FEV 1 in stable COPD [72] ; however; its long-term use is harmful for stable COPD patients because muscle strength and pulmonary function deteriorate after high doses of systemic corticosteroids. A study by Horita et al. [73] reported that long-term oral corticosteroids may increase the mortality of severe and very severe COPD patients.
Phosphodiesterase-4 Inhibitors
Roflumilast improves lung function and decreases exacerbations (frequency and hospitalizations) in patients with severe to very severe COPD [74, 75] . The REACT (Roflumilast in the Prevention of COPD Exacerbations While Taking Appropriate Combination Treatment) study showed that in COPD patients at risk of frequent or severe exacerbations and hospitalizations, receiving inhalation combination ICS/LABA therapy or triple therapy (LAMA/ICS/LABA), roflumilast significantly reduced the rate of severe exacerbations by 24.3% (p = 0.0175) and hospital admissions by 23.9% (p = 0.0209) [74] .
Antibiotics
Although prophylactic antibiotics are not recommended for routine use in patients with COPD, they may be considered in certain situations [12] . A randomized controlled study by Albert et al. reported that adding daily azithromycin (250 mg) to the usual treatment for 1 year decreased the frequency of exacerbations and improved quality of life in patients with COPD aged ≥40 years who had an increased risk of exacerbations (but without hearing impairment) [76] . A more recent study by Uzun et al. [77] confirmed the improvement in exacerbation rate in patients with COPD who received previous treatment for 3 or more exacerbations in the preceding year. Thus, azithromycin 500 mg 3 times a week might be considered in patients with severe airflow obstruction and recurrent, frequent exacerbations. Due to the potential side effects (emergence of antimicrobial resistance, gastrointestinal and ontological complaints) the indication for this therapy should be evaluated by a pneumologist.
Alpha-1 Antitrypsin Augmentation Therapy
It is suggested that this therapy may be considered for never-smokers or ex-smokers with an FEV 1 of 35-60% predicted (Evidence B) [12] . Patients with severe hereditary AATD and established emphysema may also be candidates for alpha-1 antitrypsin augmentation therapy (Evidence B) [12] .
Mucolytic and Antioxidant Agents
Antioxidant mucolytics should be considered in selected patients (Evidence A) [12] . Two meta-analyses demonstrate that long-term mucolytic or antioxidant therapy (e.g., N-acetylcysteine) may significantly reduce the frequency of exacerbations in COPD patients [78, 79] . Improvement of lung function is seen in the 1-year HIACE trial in patients with stable COPD treated with high-dose N-acetylcysteine (600 mg twice daily) [80] . The most benefit is observed in those with frequent exacerbations and only with a high dose of N-acetylcysteine (1,200 mg per day) [81] . Immunomodulators The lyophilized bacterial extract OM-85 BV is an immunomodulator used for preventing exacerbations [82] . There is no conclusive evidence as to its efficacy. One meta-analysis showed that both exacerbation and incidence rate of patients using antibiotics were reduced in COPD patients receiving OM-85 BV compared to placebo by 20% (relative risk 0.80, 95% CI 0.65-0.97) and 39% (relative risk 0.61, 95% CI 0.48-0.77) [83] , respectively, while a previous meta-analysis found only a numerical trend in favour of OM-85 BV in the exacerbation rate (relative risk 0.83, 95% CI 0.65-1.05) [82] . Further trials are required to confirm the effectiveness of OM-85 BV in patients with COPD [82, 83] .
EPs ® 7630 is an extract from the roots of the flowering plant Pelargonium sidoides effective for the treatment of URTIs and acute bronchitis. The safety and efficacy of EPs ® 7630 for the treatment of patients with stable COPD GOLD II/III is demonstrated in a multicentre, placebocontrolled double-blind study. EPs ® 7630 prolongs the median time to exacerbation compared to placebo (57 vs. 43 days; p = 0.005) [84] . [85] . Treatment with EPs ® 7630 also results in a reduction in antibiotic use and improvement in quality of life [84] [85] [86] . Further trials are required to confirm the effectiveness of EPs ® 7630 in patients with COPD.
Oxygen Therapy
Long-term oxygen therapy (> 16 h per day) is recommended to increase the survival in stable COPD patients with arterial hypoxemia (PaO 2 ≤55 mm Hg or SaO 2 ≤88%, or 55< PaO 2 < 60 mm Hg or SaO 2 = 88%), if there is evidence of pulmonary hypertension, peripheral oedema suggesting congestive cardiac failure, or polycythemia (haematocrit > 55%; Evidence A) [12, 87] . In a systematic review of 6 randomized controlled trials, a significant improvement in mortality over 5 years is observed (OR 0.42, 95% CI 0.18-0.98) for the subjects receiving oxygen therapy compared to those who do not [87] .
Pulmonary Rehabilitation
Pulmonary rehabilitation is one of the key recommended approaches in the treatment of COPD (Evidence A) [12] . It is "a comprehensive intervention based on thorough patient assessment followed by patient tailored therapies that include, but are not limited to, exercise training, education, self-management intervention aiming at behaviour change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviours" [12, 88] . A meta-analysis of 65 randomized controlled trials involving 3,822 participants concludes that pulmonary rehabilitation, including inspiratory muscle training, improves muscle strength, endurance, exercise capacity, dyspnea, quality of life and emotional function and enhances the sense of control that individuals have over their condition [89] . Pulmonary rehabilitation should be considered for most patients with COPD, although it is especially effective in patients with moderate to severe disease [12] . Programmes lasting 6-8 weeks are recommended for optimal benefit [12] .
Interventional Therapy
Bronchoscopic interventions in COPD patients with advanced emphysema are aimed at reducing hyperinflation and end-expiratory lung volume and at improving exercise tolerance, health status and lung function 6-12 months following treatment [12] . The 2 recommended bronchoscopic procedures are endobronchial valves (Evidence B) and lung coils (Evidence B) [12] .
Lung volume reduction surgery improves quality of life and survival in patients with severe emphysema and low post-rehabilitation exercise capacity (Evidence A) [12] . However, lung volume reduction surgery is associated with higher costs compared to health-care programs that do not include surgery [12] . Bullectomy results in decreased dyspnoea, improved lung function and exercise tolerance [12] .
Lung transplantation improves quality of life and functional capacity in selected patients (Evidence C) [12] .
Pharmacologic Treatment Algorithms
The GOLD guidelines propose new treatment algorithms for the initiation and subsequent escalation/de-escalation of pharmacological management of stable COPD according to the individualized assessment of symptoms and risk of exacerbations (groups A-D) [12] . A summary is shown in Figure 2 . Bronchodilators are recommended as the initial treatment for all groups (Evidence A) [12] . Longacting bronchodilators are preferred over short-acting agents except for patients with only occasional dyspnea (Evidence A) [12] . Patients in group B with persistent dyspnea should escalate to 2 bronchodilators (Evidence A) [12] . For patients in group C, a second long-acting bronchodilator is the preferred treatment option if exacerba-DOI: 10.1159/000490551 tions persist [12] . Alternatively, LABA/ICS can be considered (Evidence A) [12] . For group D, treatment can be escalated to triple inhaled therapy (ICS/LAMA/LABA) [12] . Treatment with a macrolide antibiotic (azithromycin 3× per week) can be considered in former smokers, particularly in frequent exacerbators and those requiring longterm oxygen therapy (Evidence B) and PDE-4 inhibitors (roflumilast) in patients with an FEV 1 < 50% predicated and chronic bronchitis (Evidence B) [12] .
Alpha-1 antitrypsin augmentation therapy may be considered for patients with severe hereditary AATD and established emphysema (Evidence B) [12] . Treatment options not recommended for any group include long-term ICS monotherapy (Evidence A), long-term therapy with oral corticosteroids (Evidence A) and theophylline, unless other long-acting bronchodilators are unavailable (Evidence B) [12] .
Management of Exacerbations
An acute exacerbation of COPD (AECOPD) is defined as an acute worsening of respiratory symptoms, and this results in additional therapy [12] . Some COPD patients are particularly susceptible to frequent exacerbations (defined as 2 or more exacerbations per year), and these patients have a worse health status and a higher morbidity than patients with less frequent exacerbations do. The goals of management of AECOPDs are to minimize the impact of the current exacerbation and to prevent the development of subsequent events [12] .
AECOPDs impose a substantial burden on the healthcare system and cause considerable morbidity, hospital admissions, and mortality. The risk of mortality increases by 30-43% within 12 months following an acute COPD exacerbation. Among individuals with COPD, some patients are prone to frequent exacerbations while others remain relatively protected [89] . Approximately 70-80% of COPD exacerbations are triggered by bacterial and viral infections (especially rhinovirus), but air pollution can also be an induction factor [90, 91] . Frequency of exacerbations is one of the most important determinants of health-related quality of life in patients with COPD.
In Switzerland, patients with AECOPDs have a prolonged hospital stay compared to patients in other European countries (11.3 vs. 8.7 days; p < 0.001) [92] . Moreover, the risk of in-hospital death (5.4%) is slightly elevated compared to other European countries (4.9%) but overall mortality is lower (8.1 vs. 10.9%, respectively) [92] . The recent European COPD audit recommends at least a (venous) blood gas analysis in every patient admitted to hospital with suspected severe exacerbation of COPD [92] . Currently, the number of arterial blood gas samples taken to assess the severity of exacerbations in Switzerland is comparable to other European countries (85.6 vs. 84.1%, respectively) [92] . Spirometry should also be performed before a patient is discharged from hospital or at least 4-6 weeks thereafter [92] .
Preventive Strategies
Almost half (43%) of Swiss COPD patients admitted to hospital due to an acute exacerbation are smokers in contrast to 31% in other European countries (p < 0.001) [92] . Based on the recommendations of the European COPD audit, smoking cessation should be offered to COPD patients admitted to hospital for an exacerbation [92] . In addition, patients should be informed about influenza and pneumococcal vaccinations [92] .
Bronchodilation
The mainstay of AECOPD treatment is bronchodilation with SABAs, with or without short-acting anticholinergics (Evidence C) [12] . Medical staff should be trained in the administration of inhaled and nebulized bronchodilators in all Swiss hospitals [92] . A recent European audit suggests that only 79% of patients in Swiss hospitals receive this treatment for exacerbations at admission [92] .
Systemic Glucocorticosteroids
High-quality evidence supports the treatment of AECOPD with systemic glucocorticosteroids (oral or parenteral route) (Evidence A) [92, 93] . In diagnosed patients, systemic glucocorticosteroids reduce the likelihood of treatment failure and relapse by one month, shorten the hospital stay in patients not requiring assisted ventilation and provide earlier improvement in lung function and symptoms [12, 93] . Glucocorticosteroid treatment should not be given for more than 5-7 days [94] .
Antibiotics
AECOPDs should not be treated with antibiotics, unless a bacterial infection is suspected, or the patient requires treatment in the intensive care unit (Evidence B) [12, 95] . In acute exacerbations of COPD with increased cough and sputum purulence, the use of antibiotics reduces the short-term risk of mortality by 77% and decreases the risk of treatment failure by 53% [96] . In nonfebrile exacerbations, antibiotics do not reduce treatment failure at 28 days [97] do not prolong the exacerbationfree time [98] . Antibiotic treatment should not exceed 5-7 days during an AECOPD [12, 99] . A serum procalcitonin-guided approach can reduce use and exposure to antibiotics without impacting clinical outcomes such as re-exacerbation, need for hospitalization or mortality (Evidence A) [100, 101] .
Other Recommended Pharmacological Treatments for AECOPD Methylxanthines are not recommended for treatment of AECOPD in the GOLD guidelines (Evidence B) [12, 102] . A meta-analysis evaluating the role of intravenous aminophylline during an AECOPD did not find any beneficial effect in terms of improvement of pulmonary function or symptoms [102] .
Oxygen Therapy
Oxygen therapy is a key component of hospital treatment for an exacerbation [12] . Titrating oxygen therapy to ≥90% saturation is recommended in patients with an AECOPD to avoid hypoxemia and to reduce the risk of oxygen-induced hypercapnia [12, 103] . In Switzerland, approximately 93.1% of AECOPD patients receive oxygen therapy on admission to hospital.
Non-Pharmacological Therapy
Non-invasive ventilation (NIV) is the standard of care to decrease intubation rates and mortality in patients hospitalized with AECOPD and acute respiratory DOI: 10.1159/000490551 failure [12] . NIV should be the first mode of ventilation used in COPD patients with acute respiratory failure who have no absolute contraindication because it improves gas exchange, reduces the work of breathing and the need for intubation, decreases hospitalization duration and improves survival (Evidence A) [12] . NIV is effective in reducing the need for invasive mechanical ventilation and improving short-term survival in patients with severe AECOPD. Results from a large retrospective cohort study show that NIV given to patients on admission to hospital reduces in-patient mortality, shortens length of hospital stay and lowers costs compared to those treated with invasive mechanical ventilation [104] .
